Proparacaine

Generic Name
Proparacaine
Brand Names
Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C16H26N2O3
CAS Number
499-67-2
Unique Ingredient Identifier
B4OB0JHI1X
Background

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication

Used as a local (ophthalmic) anesthetic.

Associated Conditions
Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Associated Therapies
Local Anaesthesia therapy
Clinical Trials
Related News

Acute Lymphoblastic Leukaemia Related to Lenalidomide (LenALL)

Not yet recruiting
Conditions
Cancer
First Posted Date
2024-02-09
Last Posted Date
2024-02-09
Lead Sponsor
University Hospital, Caen
Target Recruit Count
300
Registration Number
NCT06251648
Locations
🇫🇷

CHU de Caen, Caen, France

Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma

First Posted Date
2024-01-23
Last Posted Date
2024-08-19
Lead Sponsor
Stichting Hemato-Oncologie voor Volwassenen Nederland
Target Recruit Count
324
Registration Number
NCT06220032
Locations
🇳🇱

NL-Breda-AMPHIA, Breda, Netherlands

🇳🇱

NL-Almelo-ZGTALMELO, Almelo, Netherlands

🇳🇱

NL-Amstelveen-AMSTELLAND, Amstelveen, Netherlands

and more 22 locations

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

First Posted Date
2024-01-17
Last Posted Date
2024-11-28
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
40
Registration Number
NCT06207799
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

First Posted Date
2024-01-17
Last Posted Date
2024-12-17
Lead Sponsor
Oncotherapeutics
Target Recruit Count
30
Registration Number
NCT06209606
Locations
🇺🇸

Berenson Cancer Center, West Hollywood, California, United States

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

First Posted Date
2024-01-05
Last Posted Date
2024-10-31
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
39
Registration Number
NCT06192888
Locations
🇺🇸

Dana Farber Cancer Institute (Data Collection and Specimen Analysis), Boston, Massachusetts, United States

🇺🇸

Mayo Clinic (Data Collection Only), Rochester, Minnesota, United States

🇺🇸

Washington University (Data Collection Only), Saint Louis, Missouri, United States

and more 7 locations

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

First Posted Date
2024-01-05
Last Posted Date
2024-12-03
Lead Sponsor
Genmab
Target Recruit Count
1080
Registration Number
NCT06191744
Locations
🇺🇸

Rocky Mountain Cancer Centers - Boulder /ID# 261203, Boulder, Colorado, United States

🇺🇸

Christiana Care Health Service /ID# 261207, Newark, Delaware, United States

🇺🇸

Oncology Hematology Care, Inc - Blue Ash /ID# 261204, Cincinnati, Ohio, United States

and more 192 locations

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

First Posted Date
2024-01-05
Last Posted Date
2024-04-23
Lead Sponsor
Stichting European Myeloma Network
Target Recruit Count
200
Registration Number
NCT06189833
Locations
🇬🇷

St Savvas Cancer Hospital, Athens, Greece

🇩🇪

Universitätsklinikum Hamburg - Eppendorf, Hamburg, Germany

🇦🇹

Innsbruck Medical University, Innsbruck, Austria

and more 28 locations

Fixed Duration vs Continuous Daratumumab in Transplant Ineligible Older Adults With Newly Diagnosed Multiple Myeloma

First Posted Date
2023-12-27
Last Posted Date
2024-12-11
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
559
Registration Number
NCT06182774
Locations
🇨🇦

BCCA - Kelowna, Kelowna, British Columbia, Canada

🇨🇦

Verspeeten Family Cancer Centre, London, Ontario, Canada

🇨🇦

Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada

and more 15 locations

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

First Posted Date
2023-12-13
Last Posted Date
2024-10-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
70
Registration Number
NCT06169215
Locations
🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States

🇺🇸

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

and more 23 locations

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

First Posted Date
2023-11-28
Last Posted Date
2024-12-19
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
470
Registration Number
NCT06149286
Locations
🇩🇪

Clinic Frankfurt (Oder), Frankfurt, Hesse, Germany

🇹🇷

Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey

🇺🇸

David Geffen School of Medicine at UCLA, Los Angeles, California, United States

and more 121 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy